A practical guide to the use of eltrombopag in children with chronic immune thrombocytopenia

References

• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393. doi:10.1182/blood-2008-07-162503
   PubMed Web of Science ®Google Scholar
• Abrams C. Thrombocytopenia. In: Goldman L, Schafer A, eds. Goldman-Cecil Medicine. Philadelphia, PA: Saunders Elsevier; 2011:1124–1131.
   Google Scholar
• Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–4207. doi:10.1182/blood-2010-08-302984
   PubMed Web of Science ®Google Scholar
• Izak M, Bussel JB. Contemporary treatment of immune thrombocytopenia. Expert Rev Hematol. 2013;6(6):697–712. doi:10.1586/17474086.2013.841076
   PubMed Web of Science ®Google Scholar
• Wormann B. Clinical indications for thrombopoietin and thrombopoietin-receptor agonists. Transfus Med Hemotherapy Off Organ Dtsch Ges Transfusionsmedizin Immunhamatol. 2013;40(5):319–325. doi:10.1159/000355006
   Google Scholar
• Kistanguri G, McCrae KR. Immune Thrombocytopenia. Hematol Oncol Clin North Am. 2013;27(3):495–520. doi:10.1016/j.hoc.2013.03.001
   PubMed Web of Science ®Google Scholar
• Hallam S, Provan D, Newland AC. Immune thrombocytopenia – what are the new treatment options? Expert Opin Biol Ther. 2013;13(8):1173–1185. doi:10.1517/14712598.2013.801451
   PubMed Web of Science ®Google Scholar
• Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol. 2010;85(3):174–180. doi:10.1002/ajh.21616
   PubMed Web of Science ®Google Scholar
• Abrahamson PE, Hall SA, Feudjo-Tepie M, Mitrani-Gold FS, Logie J. The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review. Eur J Haematol. 2009;83(2):83–89. doi:10.1111/j.1600-0609.2009.01247.x
   PubMed Web of Science ®Google Scholar
• Arnold DM. Positioning new treatments in the management of immune thrombocytopenia. Pediatr Blood Cancer. 2013;60(Suppl 1(Journal Article)):S19–S22. doi:10.1002/pbc.24341
   PubMed Web of Science ®Google Scholar
• Beck CE, Nathan PC, Parkin PC, Blanchette VS, Macarthur C. Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials. J Pediatr. 2005;147(4):521–527. doi:10.1016/j.jpeds.2005.04.032
   PubMed Web of Science ®Google Scholar
• Palau J, Jarque I, Sanz MA. Long-term management of chronic immune thrombocytopenic purpura in adults. Int J Gen Med. 2010;3:305–311. doi:10.2147/IJGM.S4722
   PubMedGoogle Scholar
• Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 sources after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119(25):5989–5995. doi:10.1182/blood-2011-11-393975
   PubMed Web of Science ®Google Scholar
• Ghanima W, Khelif A, Waage A, et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Lond Engl. 2015;385(9978):1653–1661. doi:10.1016/S0140-6736(14)61495-1
   Google Scholar
• Labarque V, Van Geet C. Clinical practice: immune thrombocytopenia in paediatrics. Eur J Pediatr. 2014;173(2):163–172. doi:10.1007/s00431-013-2254-6
   PubMed Web of Science ®Google Scholar
• Cuker A, Neunert CE. How I treat refractory immune thrombocytopenia. Blood. April 2016. doi:10.1182/blood-2016-03-603365
   Web of Science ®Google Scholar
• Audia S, Godeau B, Bonnotte B. Is there still a place for “old therapies” in the management of immune thrombocytopenia? Rev Med Interne Fondee Par Soc Natl Francaise Med Interne. 2016;37(1):43–49. doi:10.1016/j.revmed.2015.08.007
   Google Scholar
• Mazza P, Minoia C, Melpignano A, et al. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a “real life” retrospective multicenter experience of the Rete Ematologica Pugliese (REP). Ann Hematol. 2016;95(2):239–244. doi:10.1007/s00277-015-2556-z
   PubMed Web of Science ®Google Scholar
• Bussel J. Safety and Efficacy of Eltrombopag in Splenectomized and Nonsplenectomized Patients With Immune Thrombocytopenia: Results from the EXTEND Study. June 2016.
   Google Scholar
• Reid MM. Chronic idiopathic thrombocytopenic purpura: incidence, treatment, and outcome. Arch Dis Child. 1995;72(2):125–128.
   PubMed Web of Science ®Google Scholar
• Medeiros D, Buchanan GR. Idiopathic thrombocytopenic purpura: beyond consensus. Curr Opin Pediatr. 2000;12(1):4–9.
   PubMed Web of Science ®Google Scholar
• Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000;160(11):1630–1638.
   PubMedGoogle Scholar
• Grainger JD, Young NL, Blanchette VS, Klaassen RJ. Quality of life in immune thrombocytopenia following treatment. Arch Dis Child. 2013;98(11):895–897. doi:10.1136/archdischild-2013-303784
   PubMed Web of Science ®Google Scholar
• Harris E, Tiganescu A, Tubeuf S, Mackie SL. The prediction and monitoring of toxicity associated with long-term systemic glucocorticoid therapy. Curr Rheumatol Rep. 2015;17(6):513-15-0513-0514. doi:10.1007/s11926-015-0513-4
   Web of Science ®Google Scholar
• Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013;27(3):171–178. doi:10.1016/j.tmrv.2013.05.004
   PubMed Web of Science ®Google Scholar
• Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98(4):952–957.
   PubMed Web of Science ®Google Scholar
• Sahu S, Hemlata Verma A. Adverse events related to blood transfusion. Indian J Anaesth. 2014;58(5):543–551. doi:10.4103/0019-5049.144650
   PubMedGoogle Scholar
• Rituxan. Prescribing Information. San Fransisco, CA: Genentech Inc. 2016; (Monograph).
   Google Scholar
• Kristinsson SY, Gridley G, Hoover RN, Check D, Landgren O. Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 sources follow-up. Haematologica. 2014;99(2):392–398. doi:10.3324/haematol.2013.092460
   PubMed Web of Science ®Google Scholar
• Kumar M, Lambert MP, Breakey V, et al. Sports participation in children and adolescents with immune thrombocytopenia (ITP). Pediatr Blood Cancer. 2015;62(12):2223–2225. doi:10.1002/pbc.25644
   PubMed Web of Science ®Google Scholar
• Heitink-Polle KM, Haverman L, Annink KV, Schep SJ, de Haas M, Bruin MC. Health-related quality of life in children with newly diagnosed immune thrombocytopenia. Haematologica. 2014;99(9):1525–1531. doi:10.3324/haematol.2014.106963
   PubMed Web of Science ®Google Scholar
• Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98(12):3241–3248.
   PubMed Web of Science ®Google Scholar
• Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377(9763):393–402. doi:10.1016/S0140-6736(10)60959-2
   PubMed Web of Science ®Google Scholar
• Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237–2247. doi:10.1056/NEJMoa073275
   PubMed Web of Science ®Google Scholar
• Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9664):641–648. doi:10.1016/S0140-6736(09)60402-5
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371(9610):395–403. doi:10.1016/S0140-6736(08)60203-2
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Gminski DM, Rosenberg RD. Transforming growth factor beta inhibits megakaryocyte growth and endomitosis. Blood. 1992;79(3):619–626.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol. 2007;139(3):351–362. doi: BJH6807 [pii].
   PubMed Web of Science ®Google Scholar
• Daly ME. Determinants of platelet count in humans. Haematologica. 2011;96(1):10–13. doi:10.3324/haematol.2010.035287
   PubMed Web of Science ®Google Scholar
• Brynes RK, Orazi A, Theodore D, et al. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study. Am J Hematol. 2015;90(7):598–601. doi:10.1002/ajh.24011
   PubMed Web of Science ®Google Scholar
• Ghanima W, Geyer JT, Lee CS, et al. Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up. Haematologica. 2014;99(5):937–944. doi:10.3324/haematol.2013.098921
   PubMed Web of Science ®Google Scholar
• Bussel J, Cheng G, Saleh M, Mayer B, Vasey S, Brainsky A. Incidence of Thromboembolic Events Across Eltrombopag Clinical Trials In Chronic Immune Thrombocytopenia (ITP). Blood. 2010;116(21)(Abstract):37.
   Web of Science ®Google Scholar
• Rodeghiero F. Is ITP a thrombophilic disorder? Am J Hematol. 2016;91(1):39–45. doi:10.1002/ajh.24234
   PubMed Web of Science ®Google Scholar
• Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98(1):10–23. doi:10.1007/s12185-013-1382-0
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Ruggeri M. Treatment of immune thrombocytopenia in adults: the role of thrombopoietin-receptor agonists. Semin Hematol. 2015;52(1):16–24. doi:10.1053/j.seminhematol.2014.10.006
   PubMed Web of Science ®Google Scholar
• Saleh MN, Bussel JB, Cheng G, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013;121(3):537–545. doi:10.1182/blood-2012-04-425512
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363(20):1889–1899. doi:10.1056/NEJMoa1002625
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Giagounidis A, et al. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials. Eur J Haematol. 2013;91(5):423–436. doi:10.1111/ejh.12181
   PubMedGoogle Scholar
• Tarantino MD, Bussel JB, Blanchette VS, et al. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet Lond Engl. 2016;388(10039):45–54. doi:10.1016/S0140-6736(16)00279-8
   Google Scholar
• Mathias SD, Li X, Eisen M, Carpenter N, Crosby RD, Blanchette VS. A Phase 3, randomized, double-blind, placebo-controlled study to determine the effect of romiplostim on health-related quality of life in children with primary immune thrombocytopenia and associated burden in their parents. Pediatr Blood Cancer. 2016; (Journal Article). doi:10.1002/pbc.25984
   Web of Science ®Google Scholar
• Tarantino MD, Bussel JB, Blanchette VS, et al. Safety and efficacy of long-term open-label dosing of subcutaneous (SC) romiplostim in pediatric patients with immune thrombocytopenia (ITP). ASH Annu Meet Abstr. 2015; (Journal Article). doi:S0140-6736(16)00279-8 [pii].
   Google Scholar
• Bussel JB, de Miguel PG, Despotovic JM, et al. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol. 2015;2(8):e315–e325. doi:10.1016/S2352-3026(15)00114-3
   PubMed Web of Science ®Google Scholar
• Grainger JD, Locatelli F, Chotsampancharoen T, et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet Lond Engl. 2015; (Journal Article). doi: S0140-6736(15)61107-2 [pii].
   Google Scholar
• Crom WR. Pharmacokinetics in the child. Environ Health Perspect. 1994;102 Suppl 11(Journal Article):111–117.
   PubMed Web of Science ®Google Scholar
• Novartis. PROMACTA [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation.
   Google Scholar
• Nguyen TT, Palmaro A, Montastruc F, Lapeyre-Mestre M, Moulis G. Signal for thrombosis with eltrombopag and romiplostim: a disproportionality analysis of spontaneous reports within VigiBase((R)). Drug Saf. 2015;38(12):1179–1186. doi:10.1007/s40264-015-0337-1
   PubMed Web of Science ®Google Scholar
• Merli P, Strocchio L, Vinti L, Palumbo G, Locatelli F. Eltrombopag for treatment of thrombocytopenia-associated disorders. Expert Opin Pharmacother. 2015;16(14):2243–2256. doi:10.1517/14656566.2015.1085512
   PubMed Web of Science ®Google Scholar
• Gonzalez-Porras JR, Mingot-Castellano ME, Andrade MM, et al. Use of eltrombopag after romiplostim in primary immune thrombocytopenia. Br J Haematol. 2015;169(1):111–116. doi:10.1111/bjh.13266
   PubMed Web of Science ®Google Scholar
• Newland A, Godeau B, Priego V, et al. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. Br J Haematol. 2016;172(2):262–273. doi:10.1111/bjh.13827
   PubMed Web of Science ®Google Scholar
• Grainger J, Sirachainan N, Wire M, et al. Modeling and Simulation (M&S) Support Eltrombopag (EPAG) dosage escalation based on platelet count for pediatric patients with persistent or chronic immune thrombocytopenia (cITP). EHA Congr Abstr. 2016; E1420 (Journal Article).
   Google Scholar
• Dyer L, Furze C, Maddox C, Sales R. Administration of medicines. In Trigg E, Mohammed T, eds. Practices in Children's Nursing. UK: Elsevier; 2006:45.
   Google Scholar
• Watt S. Safe administration of medicines to children: part 1. Paediatr Nurs. 2003;15(4) (Journal Article):40–43.
   Google Scholar
• Koufman J. The dangers of eating late at night. The New York Times. 2014:SR4.
   Google Scholar
• Morr S, Cuartas E, Alwattar B, Lane JM. How Much calcium is in your drinking water? A survey of calcium concentrations in bottled and tap water and their significance for medical treatment and drug administration. HSS J. 2006;2(2):130–135. doi:10.1007/s11420-006-9000-9
   PubMedGoogle Scholar
• Chang L, Price S, Perkins K, et al. Mycophenolate Mofetil and Thrombopoietin Receptor Agonists in the Treatment of Refractory Thrombocytopenia in Patients with Autoimmune Lymphoproliferative Syndrome. ASH Annu Meet Abstr. 2011; (Journal Article).
   Google Scholar
• Townsley D, Dumitriu B, Scheinberg P, et al. eltrombopag added to standard immunosuppression for aplastic anemia accelerates count recovery and increases response rates. Blood. 2015;126: LBA-2 (Abstract).
   Web of Science ®Google Scholar
• Anwer F, Yun S, Nair A, Ahmad Y, Krishnadashan R, Deeg HJ. Severe Refractory immune thrombocytopenia successfully treated with high-dose pulse cyclophosphamide and eltrombopag. Case Rep Hematol. 2015;2015(Journal Article):583451. doi:10.1155/2015/583451
   PubMedGoogle Scholar
• Bussel JB, Buchanan GR, Nugent DJ, et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood. 2011;118(1):28–36. doi:10.1182/blood-2010-10-313908
   PubMed Web of Science ®Google Scholar
• Mokhtar GM, Tantawy AA, El Sherif NH. Romiplostim therapy in children with unresponsive chronic immune thrombocytopenia. Platelets. 2012;23(4):264–273. doi:10.3109/09537104.2011.619601
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Macahilig C, Grotzinger KM, et al. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. Int J Hematol. 2015;101(3):255–263. doi:10.1007/s12185-014-1731-7
   PubMed Web of Science ®Google Scholar
• Gonzalez-Lopez TJ, Pascual C, Alvarez-Roman MT, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol. 2015;90(3):E40–E43. doi:10.1002/ajh.23900
   PubMed Web of Science ®Google Scholar
• Mori M, Kato M, Koh K, Hanada R. Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP. Rinsho Ketsueki. 2015;56(5):511–513. doi:10.11406/rinketsu.56.511
   PubMedGoogle Scholar
• Pathak S, Roth M, Verma A, Steidl U. Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders. Expert Opin Drug Metab Toxicol. 2013;9(12):1667–1675. doi:10.1517/17425255.2013.858119
   PubMed Web of Science ®Google Scholar
• Scaramucci L, Giovannini M, Niscola P, Tendas A, Perrotti A, De Fabritiis P. Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura. Blood Transfus Trasfus Sangue. 2014;(Journal Article):1–3. doi:10.2450/2014.0246-13
   PubMed Web of Science ®Google Scholar
• Piccin A, Amaddii G, Natolino F, Billio A, Cortelazzo S. Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim. Blood Transfus Trasfus Sangue. 2014;12(Suppl 1) (Journal Article):s149–s150. doi:10.2450/2013.0289-12
   PubMed Web of Science ®Google Scholar
• Amgen. NPLATE [package insert]. Thousand Oaks, CA: Amgen, Inc.; 2016.
   Google Scholar
• Gómez-Almaguer D, Herrera-Rojas M, Jaime-Pérez J, et al. Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. Blood 123 2014;25 (Abstract).
   Google Scholar
• Bussel J, Shah KM, Brigstocke S, Torneten S. Tapering Eltrombopag in Patients with Chronic ITP: How Successful Is This and in Whom Does It Work? In: Blood. 2015;126:1054.
   Web of Science ®Google Scholar
• Biagiotti C, Carrai V, Bacchiarri F, Di Gioia M, Raugei G, Bosi A. Persistent remission of chronic immune thrombocytopenia after thrombopoietin mimetics discontinuation. Haematologica. 2015;Conference Publication: (var.pagings). 100(124) (Journal Article).
   Google Scholar
• Grainger JD, Routledge DJM, Kruse A, et al. Thrombopoietin receptor agonists in paediatric ITP patients: long term follow up data in 34 patients. Blood. 2014;124(21):4206–4206.
   Web of Science ®Google Scholar
• Keefe P, Morrissey M, McGuinn C, Bussel J. Randomized Double-Blind Study of Increasing Doses of Eltrombopag in Patients with Chronic ITP. Blood 126 2015;23 (Abstract).
   Google Scholar